DERIVES D'AMINOQUINOLINE ET D'AMINOPYRRIDINE ET LEUR UTILISATION COMME LIGANDS D'ADENOSINE A3

摘要

Aminoquinoline and aminopyridine derivatives (I) are new. Aminoquinoline and aminopyridine derivatives of formula (I), their optically active isomers, salts and solvates are new. [Image] R 1>, R 2>H or 1-4C alkyl; R 3>phenyl, thienyl, furyl (all optionally substituted by at least one 1-4C alkyl, 1-4C alkoxy or halo), 5-6 membered heteroaromatic ring (optionally substituted by 1-4C alkyl, 1-4C alkoxy or halo and containing either 1-3 N, N or S, or N or O atoms), H or R 1>; R 4>, R 5>H; or R 4>+R 5>1,3-butadienyl group optionally substituted by methylenedioxy, 1-4C alkyl, 1-4C alkoxy, halo or OH; R 6>H, CN, aminocarbonyl, 1-4C alkoxycarbonyl or carboxy; R 7>phenyl, benzyl, thienyl, furyl (all optionally substituted by at least one 1-4C alkyl, 1-4C alkoxy, halo, methylenedioxy, OH, CF 3 or CN), 5-6 membered heteroaromatic ring (optionally substituted by 1-4C alkyl, 1-4C alkoxy or halo and containing either 1-3 N, N or S, or N or O atoms) or H; X : -CH 2, -NH, -NR 8>, S, O, sulfo or sulfoxy group; R 8>1-4C alkyl or 3-6C cycloalkyl; and n : 0-2. Independent claims are also included for: (1) preparation of (I); and (2) intermediate compounds of formula (II)-(IV) (structures not given in the specification. ACTIVITY : Antiinflammatory; Antiallergic; Hypotensive; Dermatological; Antiarthritic; Immunosuppressive; Antipsoriatic; Ophthalmological; Antidiabetic; Antirheumatic; Vasotropic; Antiarrhythmic; Antiasthmatic; Cardiant; Nephrotropic; Antitumor. MECHANISM OF ACTION : Adenosine A3 Antagonist In tests, compounds (I) displayed K i values of 0.14-0.15 nM. No specific data given.